HEMOPHILIA B
Clinical trials for HEMOPHILIA B explained in plain language.
Never miss a new study
Get alerted when new HEMOPHILIA B trials appear
Sign up with your email to follow new studies for HEMOPHILIA B, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
One-Time gene shot could tame hemophilia b bleeding
Disease control OngoingThis study tests a single-dose gene therapy (BBM-H901) in 32 adults with severe hemophilia B, a condition where blood does not clot properly. The treatment uses a harmless virus to deliver a working gene that helps the body produce its own clotting factor. The goal is to reduce b…
Matched conditions: HEMOPHILIA B
Phase: PHASE2, PHASE3 • Sponsor: Shanghai Xinzhi BioMed Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 08:34 UTC
-
One-Shot gene therapy could tame hemophilia b bleeding
Disease control OngoingThis study tests a single intravenous dose of gene therapy (AskBio009) in up to 30 adults with hemophilia B, a bleeding disorder. The therapy delivers a working copy of the factor IX gene to help the body produce its own clotting factor. The main goal is to check safety, but rese…
Matched conditions: HEMOPHILIA B
Phase: PHASE1, PHASE2 • Sponsor: Baxalta now part of Shire • Aim: Disease control
Last updated May 26, 2026 08:33 UTC
-
Gene therapy breakthrough offers hope for hemophilia b patients
Disease control OngoingThis study tests a gene therapy (PF-06838435) for men with severe hemophilia B, a bleeding disorder. It aims to see if a single treatment can safely help the body produce its own clotting factor, reducing or stopping the need for regular infusions. Participants are followed for y…
Matched conditions: HEMOPHILIA B
Phase: PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated May 22, 2026 13:51 UTC
-
One-Time gene therapy could slash bleeding in hemophilia b
Disease control OngoingThis study tests a one-time gene therapy for adult men with moderate to severe hemophilia B, a bleeding disorder. The therapy delivers a working gene to help blood clot normally. Researchers will compare bleeding rates before and after treatment over 6 years. 51 participants will…
Matched conditions: HEMOPHILIA B
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated May 20, 2026 11:57 UTC
-
New hope for hemophilia b: Long-Lasting clotting factor under study
Disease control OngoingThis study tests a new drug called rIX-FP, which is a long-lasting clotting factor, in 23 Chinese men with hemophilia B. The goal is to see how well it prevents and treats bleeding episodes when given regularly. Participants receive the drug as a routine shot to keep their clotti…
Matched conditions: HEMOPHILIA B
Phase: PHASE3 • Sponsor: CSL Behring • Aim: Disease control
Last updated May 18, 2026 12:07 UTC
-
Hemophilia b study tracks bleeding events, no new drug tested
Knowledge-focused OngoingThis study looks at men with Hemophilia B who are already on regular factor IX therapy to prevent bleeding. Researchers will track bleeding events, treatment use, and quality of life for at least 6 months. No experimental treatment is given—the goal is to gather information for f…
Matched conditions: HEMOPHILIA B
Sponsor: Regeneron Pharmaceuticals • Aim: Knowledge-focused
Last updated May 26, 2026 08:41 UTC